Sepsis in Transplanted Patients: Beyond Antibiotic Therapy

Transplantation Proceedings

Volumn 40, Issue 4, 2008, Pages 1207-1211

  Perri, A ^a   Fumagalli, R ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; DANAPAROID; DROTRECOGIN; GANCICLOVIR; HEPARIN; IMMUNOGLOBULIN; PLACEBO; TACROLIMUS; THYMOCYTE ANTIBODY;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ARTICLE; BLEEDING; BLOOD CLOTTING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG SCREENING; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; PANCREAS ISLET TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; TOXOPLASMOSIS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; HUMANS; IMMUNOSUPPRESSION; INFECTION; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 44849099047     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.118     Document Type: Article

References (58)

1. Kalil A.C., Dakroub H., and Freifeld A.G. Sepsis and solid organ transplantation. Curr Drug Targets 8 (2007) 533
2. Al-Sabah S., Goldberg P., and Qureshi S.T. Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alfa (activated). Transplant Infect Dis 9 (2007) 233
3. Grochowiecki T., Nazarewski S., Meszaros J., et al. Use of drotrecogin alpha (recombinant human activated protein C, rhAPC) in the treatment of severe sepsis induced by graft pancreatitis after simultaneous pancreas and kidney transplantation: a case report. Transplant Proc 38 (2006) 276
4. Elias M., Bisharat N., Goldstein L.H., et al. Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient. Eur J Clin Microbiol Infect Dis 23 (2004) 212
5. Pastores S.M., Papadopoulos E., van den Brink M., et al. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C. Bone Marrow Transplant 30 (2002) 131
6. Kulkarni S., Naureckas E., and Cronin D.C. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplant 75 (2003) 899
7. Daniels T.L., Stephen Dummer J., Bernard G.R., et al. A case series of drotrecogin alfa (activated) in lung transplant recipients. Transplant 81 (2006) 1739
8. U.S. Food and Drug Administration. [homepage on the Internet]. www.fda.gov
9. Esmon C.T. Regulation of blood coagulation. Biochim Biophys Acta 1477 (2000) 349
10. Grinell B.W., and Joyce D. Recombinant human activated protein C: a system modulator of vascular function for tretment of severe sepsis. Crit Care Med 29 Suppl (2001) S53
11. Bernard G.R. Drotrecogin alfa (activated) (recombinant human activated protein C.) for the treatment of severe sepsis. Crit Care Med 31 1 Suppl (2003) S85
12. Hoffmann J.N., Fertmann J.M., and Jauch K.W. Microcirculatory disorders in sepsis and transplantation: therapy with natural coagulatory inhibitors antithrombin and activated protein. C Curr Opin Crit Care 12 (2006) 426
13. Deresinski S.C. Hyperimmune products in the prevention and therapy of infectious disease: a report of a hyperimmune products expert advisory panel. Bio Drugs 14 (2000) 147
14. Rubin R.H. Infection in the organ transplant recipient. In: Rubin R.H., and Young L.S. (Eds). Clinical approach to infection in the compromised host. 3rd ed. (1994), Plenum Publishing, New York 629
15. Winston D.J., Emmanouilides C., and Busuttil R.W. Infections in liver transplant recipients. Clin Infect Dis 21 (1995) 1077
16. Rubin R.H. Infectious disease complications of renal transplantation. Kidney Int 44 (1993) 221
17. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. Medical Progress 338 (1998) 1741
18. Burik J.V., and Weidsdorf D. Infections in recipient of bone marrow transplantation. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases (2000), Churchill Livingstone, New York 3136
19. Roy V., Ochs L., and Weisdorf D. Late infections following bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 26 (1997) 1
20. Winston D.J., Schiffman G., Wang D.C., et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 91 (1979) 835
21. Hammarstrom V., Pauksen K., Svensson H., et al. Serum immunoglobulin levels in relation to levels of specific antibodies in allogenic and autologous bone marrow transplant recipients. Transplantation 69 (2000) 1582
22. Knecht H., Jost R., Gmur J., et al. Functional hyposplenia after allogenic bone marrow transplantation is detected by epinephrine stimulation test and splenic ultrasonography. Eur J Haematol 41 (1988) 382
23. Farquhar I., Martin C.M., Lam C., et al. Decreased capillary density in vivo in bowel mucosa of rats with normotensive sepsis. J Surg Res 61 (1996) 190
24. 2 extraction in sepsis. Am J Physiol 282 (2002) H156
25. Levo M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 16 (2001) 167
26. Sakr Y., Dubois M.J., De Backer D., et al. Persistent microvasculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 32 (2004) 1825
27. De Backer D., Verdant C., Chierego M., et al. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 34 (2006) 1918
28. Rubin R.H. Preemptive therapy in immunocompromised hosts. N Engl J Med 324 (1991) 1057
29. Rubin R.H., and Tolkoff-Rubin N.E. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 37 (1993) 619
30. Hibberd P.L., Tolkoff-Rubin N.E., Conti D., et al. Preemptive ganciclovir therapy to prevent CMV disease in CMV-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 123 (1995) 18
31. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR 49 (2000) 1
32. Basgoz N., and Preiksaitis J. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 9 (1995) 901
33. Ho M., Miller G., Atchison R.W., et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 152 (1985) 876
34. Hoffmann J.N., and Faist E. Coagulation inhibitor replacement during sepsis: useless?. Crit Care Med 28 (2000) 574
35. Johnson K., Aarden L., Choi Y., et al. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 87 (1996) 5051
36. Hoffmann J.N., Vollmar B., Inthorn, et al. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol 279 (2000) C98
37. Neviere R., Tournoys A., Mordon S., et al. Antithrombin reduces mesenteric venular leucocyte interactions and small intestine injury in endotoxemic rats. Shock 15 (2001) 220
38. Maksan S.M., Gebhard M.M., and Schmidt J. Impact of antithrombin on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: an in vivo analysis. World J Gastroenterol 11 (2005) 4997
39. Hoffmann J.N., Vollmar B., Inthorn, et al. Antithrombin effects on endotoxin-induced microcirculatory disorders are mainly mediated by its interaction with microvascular endothelium. Crit Care Med 30 (2002) 218
40. Hoffmann J.N., Vollmar B., Laschke M., et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 88 (2002) 242
41. Iba T., Kidokoro A., Fukanaga M., et al. Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intens Care Med 31 (2005) 1101
42. Hoffmann J.N., Wiedemann C.J., Juers M., et al., KyberSept investigators. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. J Thromb Haemost 95 (2006) 850
43. Kienast J., Juers M., Wiedermann C.J., et al., KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4 (2006) 90
44. Bernard G.R., Vincent J.L., Laterre P.F., et al., Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficancy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 344 (2001) 699
45. Vincent J.L., Bernard G.R., Beale R., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 (2005) 1
46. http://www.emea.eu.int/xhumandocs/PDFs/EPAR/xigris/H-396-P-en.pdf
47. Cattaneo D., Genovesi M., Nicolini A., et al. Immunocompromised patient severe sepsis treated with xigris. Minerva anestesiologica (2004) Sept
48. Sullivan K.M., Kopecky K.J., Jocom J., et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323 (1990) 705
49. Graham-Pole J., Camitta B., Casper J., Elfenbeim G., et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant 3 (1988) 559
50. Peterson F.B., Bowden R.A., Thornquist M., et al. The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplant 2 (1987) 141
51. Wolff S.N., Fay J.N., Herzig R.H., et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 118 (1993) 937
52. Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842
53. Sanchez-Quijano A., Pineda J.A., Lissen E., et al. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1 (1988) 1245
54. Feray C., Gigou M., Samuel D., et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 128 (1998) 810
55. Cantarovich D., Karam G., Giral-Classe M., et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 54 (1998) 1351
56. Mestre M., Bas J., Alsina J., et al. Depleting effect of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation. Transplant Proc 31 (1999) 2254
57. Mariat C., Alamartine E., Diab N., et al. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int 11 (1998) 231
58. Huurman V.A., Kalpoe J.S., Van de Linde P., et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 29 (2006) 842